Home World News EMA Recommends Extending Indications for Lisocabtagene Maraleucel World News EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 279 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR England slips further off-track for smokefree 2030 target December 29, 2022 Immune Checkpoint Inhibitor Induced Thyroiditis Associated with a Large Reduction in... May 20, 2021 Peptide Receptor Radionuclide Therapy [177Lu]Lu-Edotreotide Prolongs PFS in Patients with Advanced,... July 28, 2026 Studying Genes and Proteins Together Sheds New Light on Colon Cancer May 28, 2019 Load more HOT NEWS Educators Raise Money in Memory of Teacher Who Dedicated Herself to... Lung cancer screening can’t leave anyone in the UK behind Coffee Shop Owner Learns He Has Terminal Cancer – So Competitor... Picture Showing A Realistic View Of A Woman’s Milk Ducts Goes...
